Celgene Announces Study of Bortezomib Added to Revlimid and Dexamethasone Backbone Therapy Presented at #ASH2015

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Celgene Corporation (NASDAQ: CELG) today announced that the addition of bortezomib to REVLIMID (lenalidomide) and low-dose dexamethasone (RVd), the standard of myeloma therapy, significantly improved progression-free survival (PFS) compared to lenalidomide and low-dose dexamethasone (Rd) in patients newly-diagnosed with multiple myeloma. The phase 3 study was conducted by SWOG, a publicly funded international cancer clinical trials network and presented at the 57th American Society of Hematology Annual Meeting. In the 471-patient study, patients receiving RVd achieved a median PFS of 43 months compared to a median PFS of 30 months for patients who received Rd alone (HR = 0.712, 96% CI, one-sided p=0.0018 (two-sided p=0.0037)). The data also show that overall survival (OS) was improved

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

See full press release